Severe Nocturnal Hypoxemia, Not Just Obstructive Sleep Apnea, Predicts Reduced Survival in Non-Small Cell Lung Cancer Patients
Posted innews Oncology Respiratory

Severe Nocturnal Hypoxemia, Not Just Obstructive Sleep Apnea, Predicts Reduced Survival in Non-Small Cell Lung Cancer Patients

The NEOSAS-GFPC study demonstrates that severe sleep-related hypoxemia is an independent predictor of increased mortality in NSCLC patients, highlighting the clinical importance of monitoring nocturnal oxygen saturation beyond traditional apnea indices to improve prognostic accuracy and patient care.
Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care
Posted inAllergy & Immunology Clinical Updates news Respiratory

Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care

This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocating for a holistic approach to complex patient management.
Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial
Posted inAllergy & Immunology news Respiratory

Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial

The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammatory biomarkers.
Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids
Posted inAllergy & Immunology news Respiratory

Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids

The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new evidence base for anti-inflammatory reliever strategies in moderate asthma.
Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification
Posted innews Pathology & Lab Medicine Respiratory

Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification

Researchers introduce the Mucin Quantitative Score (MUCQ), a novel metric combining mucin concentration and composition. Validated in the SPIROMICS cohort, MUCQ outperforms traditional total mucin measurements in identifying chronic bronchitis, offering a more precise tool for diagnosing and tracking muco-obstructive lung diseases.
Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial
Posted inInternal Medicine news Respiratory

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managing this debilitating and often refractory symptom.
Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade
Posted innews Oncology Respiratory

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual checkpoint inhibition as a potent chemotherapy-free neoadjuvant alternative.
High PEEP and Recruitment Manoeuvres Fail to Reduce Pulmonary Complications in One-Lung Ventilation: Insights from the PROTHOR Trial
Posted inAnesthesiology news Respiratory

High PEEP and Recruitment Manoeuvres Fail to Reduce Pulmonary Complications in One-Lung Ventilation: Insights from the PROTHOR Trial

The international PROTHOR trial reveals that using higher PEEP and recruitment manoeuvres during one-lung ventilation does not decrease postoperative pulmonary complications compared to a lower PEEP strategy, while notably increasing intraoperative hemodynamic risks like hypotension and arrhythmias.